News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

All Releases

01 March 2012 CSL Behring Recognized As A "Pioneer" By European Organisation
For Rare Diseases (EURORDIS)

CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat congenital bleeding disorders, immune deficiencies, hereditary angioedema and inherited respiratory disease, is a subsidiary of CSL Limited (ASX:CSL).

> Read More
24 February 2012 First patient screened in CSL Behring global Phase I/III study of recombinant single-chain factor VIII

Vienna, Austria, 23 February, 2012— CSL Behring has announced that the first patient has been screened in its recombinant coagulation single-chain factor VIII (rFVIII) trial, part of the AFFINITY clinical trial program. The CSL Behring rFVIII, called ‘rVIII-SingleChain’, is a novel molecule being studied for the treatment of hemophilia A. It is being developed by CSL Behring, in collaboration with its parent company, CSL Limited (ASX:CSL).

> Read More
21 February 2012 Medical Experts Who Participated In CSL Behring's Key Issues Dialogue Prefer Albumin For Fluid Management

Thought leaders from the medical community in Europe and the U.S. examined the pros and cons of using albumin in treating liver disease and sepsis, and in cardiac surgery, during CSL Behring’s Key Issues Dialogue — "Albumin in Clinical Fluid Management."

> Read More
16 February 2012 CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors

CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX. CSL Behring is developing this therapy in collaboration with its parent company CSL Limited (ASX: CSL).

> Read More
15 February 2012 CSL Behring Announces 2012 Interlaken Leadership Awards Recipients

CSL Behring announced today the four recipients of the 2012 Interlaken Leadership Awards. Now in its second year, the Interlaken Leadership Awards program recognizes scientists whose proposals are likely to advance innovative medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders. The total value of the four awards is estimated to be more than $1 million USD.

> Read More
Page 25 of 51 First | Previous | Next | Last

LinkedIn Twitter Facebook Google+